23 May
2024
PureTech Health plc
PureTech to Present at the Jefferies Global
Healthcare Conference
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to changing
the lives of patients with devastating diseases, today announced
that Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer,
and Eric Elenko, Ph.D., Co-founder and President, will participate
in a fireside chat at the Jefferies Global Healthcare Conference on
Thursday, June 6th, 2024, at 10:00am EDT / 3:00pm BST. A
webcast of the presentation will be available at https://investors.puretechhealth.com.
About PureTech
Health
PureTech is a clinical-stage biotherapeutics
company dedicated to giving life to new classes of medicine to
change the lives of patients with devastating diseases. The Company
has created a broad and deep pipeline through its experienced
research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced
both internally and through its Founded Entities. PureTech's
R&D engine has resulted in the development of 29 therapeutics
and therapeutic candidates, including two that have received both
U.S. FDA clearance and European marketing authorization and a third
(KarXT) that has been filed for FDA approval. A number of these
programs are being advanced by PureTech or its Founded Entities in
various indications and stages of clinical development, including
registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points.
For more information, visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Cautionary Note
Regarding Forward-Looking Statements
This press release contains statements that are or
may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to our upcoming presentation at
the Jefferies Global Healthcare Conference and our future
prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2023 filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
UK/EU
Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US Media
Nichole Bobbyn
+1 774 278 8273
nichole@tenbridgecommunications.com